ArticleFrontiers in immunology2026
Polysaccharides from Radix Hedysari exhibited preventive effects against DSS-induced ulcerative colitis in C57BL/6 mice.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hedysarum polysaccharide (HPS), the major bioactive constituent of Radix Hedysari, possesses anti-inflammatory activity; however, few studies have explored its application for ulcerative colitis (UC). In this study, HPS-80 was extracted using combined complex-enzyme hydrolysis and ultrasonication. We further evaluated its preventive effects and underlying mechanisms in a dextran sulfate sodium (DSS)-induced UC model in C57BL/6 mice. Results showed HPS-80 significantly improved DSS-induced UC symptoms (weight loss, hematochezia, colon shortening) and reduced Disease Activity Index (DAI). Mechanistically, it inhibited pro-inflammatory factors Tumor Necrosis Factor-alpha(TNF-α),Interleukin-6, (IL-6), alleviated oxidative stress, upregulated tight junction proteins occludin, claudin-1(ZO-1), and modulated intestinal microbiota (suppressed harmful bacteria like Bacteroidota, enriched beneficial ones like Firmicutes and Akkermansia). Conclusion: HPS-80 exerts protective effects against UC via anti-inflammatory, antioxidant and gut-microbiota-regulating capacities. It is a promising candidate agent for UC prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.